Long-term transfer-factor treatment for multiple sclerosis

Lancet. 1978 Apr 22;1(8069):851-3. doi: 10.1016/s0140-6736(78)90194-0.

Abstract

In groups of 16 patients with multiple sclerosis, 13 months' double-blind treatment with transfer factor from random normal donors differed from placebo treatment only in producing a temporary restoration of lymphocyte reactivity to measles virus antigen, and did not arrest the degeneration of nerve tissue.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antigens, Viral
  • Clinical Trials as Topic
  • Double-Blind Method
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Injections, Subcutaneous
  • Lymphocyte Activation
  • Lymphocytes / immunology
  • Male
  • Measles virus / immunology
  • Middle Aged
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / therapy*
  • Time Factors
  • Transfer Factor / administration & dosage*
  • Transfer Factor / therapeutic use

Substances

  • Antigens, Viral
  • Transfer Factor